 CAMBRIDGE Mass., March 16, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. NASDAQ: RUBY Rubius, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announces the pricing of an upsized underwritten public offering of 6,896,552 shares of its common stock at a public offering price of 29.00 per share. The gross proceeds to Rubius from the offering are expected to be approximately 200 million, before deducting the underwriting discounts and commissions and other offering expenses. Rubius has granted the underwriters a 30-day option to purchase up to an additional 1,034,482 shares of its common stock. 